Mangoceuticals (MGRX) Gains from Investment Securities (2022 - 2026)

Mangoceuticals has disclosed Gains from Investment Securities across 5 years of filings, most recently posting $2.2 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $2.2 million, up 1276.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 million (up 1276.6% YoY), and the FY2025 annual result was $2.0 million, up 14900.38% from the prior year.
• Gains from Investment Securities came in at $2.2 million for Q1 2026 at Mangoceuticals, up from $2.0 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $2.4 million in Q1 2024 to a low of $13333.0 in Q4 2024.
• The 5-year median for Gains from Investment Securities is $156666.0 (2024), against an average of $1.0 million.
• Peak annual rise in Gains from Investment Securities reached 14900.38% in 2025, while the deepest fall reached 93.38% in 2025.
• Mangoceuticals' Gains from Investment Securities stood at $83333.0 in 2022, then rose by 12.0% to $93333.0 in 2023, then sank by 85.71% to $13333.0 in 2024, then surged by 14900.38% to $2.0 million in 2025, then increased by 7.83% to $2.2 million in 2026.
• The last three Gains from Investment Securities figures came in at $2.2 million (Q1 2026), $2.0 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.